Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
SPAC: Mr. Jean-François OTT appointed CEO of SPAC
SPAC: Mr. Jean-François OTT appointed CEO of SPAC
SPAC: Mr. Jean-François OTT appointed CEO of SPAC
BILENDI: Bilendi announces the completion of the the acquisition of the respondi group
BILENDI: Bilendi announces the completion of the the acquisition of the respondi group
BILENDI: Bilendi announces the completion of the the acquisition of the respondi group
Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research & Development
Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research & Development
Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research & Development
BILENDI: Bilendi acquires the respondi Group,  a European player in data collection for market research
BILENDI: Bilendi acquires the respondi Group, a European player in data collection for market research
BILENDI: Bilendi acquires the respondi Group, a European player in data collection for market research